Zhitong Finance App News, Meibang Co., Ltd. (605033.SH) announced that the company plans to use its own capital to increase the capital of its wholly-owned subsidiary Shaanxi Nuozheng Biotechnology Co., Ltd. (“Nuozheng Biotech”) by 80 million yuan, and plans to invest 1 million US dollars in the Hong Kong Special Administrative Region to establish a wholly-owned overseas subsidiary, Meibang Pharmaceutical (Hong Kong) Co., Ltd. (“Hong Kong Company”). The registered capital of the Hong Kong company is HK$500,000. After the capital increase, the company's shareholding ratio in Nuozheng Biotech remained unchanged.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.